REMARKS

With this response, claims 10-58 are pending. Claims 39, 40, 42, 43, and 47 have been canceled without prejudice or disclaimer of the underlying subject matter. Claims 24, 44, and 49-58 have been amended. Support for the claim amendments can be found throughout the specification and the claims as originally filed. Additional support for such amendments and new claims will be apparent to one of skill in the art. Upon entry of the foregoing amendments, claims 10-38, 41, 44-46 and 48-58 will be pending. Support for the amendments to the specification can be found throughout the application, in particular at page 5, lines 14 to 31; figures 3C, 3D, 4A, 4B, and 6A-6D; and the examples, including examples 4, 5, and 6. These sections describe two subjects with impaired glucose tolerance, referred to as D01 and D02, and two subjects with type 2 diabetes mellitus, referred to as D07 and D09. Each of the subjects had results of saline infusion and GLP-1 infusion. In example 6 and Figures 6A-6D, there is described a comparison of normalized spectral power during saline infusion and GLP-1 infusion for two subjects, D02 and D07. Hence, from this there should be four graphs to compare, saline infusion for D02, GLP-1 infusion for D02, saline infusion for D07, and GLP-1 infusion for D07. The description in the specification refers to the 4 graphs in the figures. For example, on page 23, lines 3-4, of the specification, it states "[t]hese [Figures 6A-6D] correspond to the data shown in Figures 3C and 3D, and Figures 4A and 4B." Accordingly, Applicants submit that the amendments find support in the specification and no new matter is being added by the present amendments.

Initially, Applicants acknowledge and thank the Examiner for indicating that "[t]he objection to the specification and claims and the rejections under 35 U.S.C. 112, second paragraph, 35 U.S.C. 103(a) and 35 U.S.C. 102(b) for composition claims (i.e. canceled claims 1-9) are withdrawn." *Office Action mailed December 27, 2004*, at page 2.